Samus Therapeutics, Inc. is a privately held, Boston-based biotech company focused on addressing areas of high unmet medical need in cancer and neurodegenerative diseases through an innovative approach to protein degradation and restoration of normal cellular pathways.

Our scientific platform is based on protein degradation through epichaperome inhibition.  Icapamespib (PU-AD) is being studied in brain cancer and neurodegenerative disorders. A Phase1b study in recurrent malignant glioma was initiated in Dec 2021.  Zelavespib (PU-H71) is being evaluated in a Phase 1 study in myelofibrosis